NASDAQ · REVB

Revelation Biosciences, Inc.

Healthcare · Biotechnology

$0.95▲ 3.26% ($0.03)at close

After hours$0.97▲ 1.98%7:30 PM ET

52-week

$0.88$6.76

Market cap

$3.71M

P/E

-0.14

EPS (TTM)

-$2.81

Next earnings

Nov 5, 2026

No multiple

What the market price implies · Reverse DCF

Selected forecast · Base scenario

Unavailable · actual 10-year annualized revenue growth

Year 1 growth: —

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.95

Estimated value / share

Unavailable

Base scenario

USD

Need reported operating working-capital balances or comparable changes in working capital to forecast reinvestment; an unknown requirement cannot be treated as zero.

Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.

Year 1 growth — · Ending margin — · Discount rate 7%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: Not supplied
Data refreshed: Sep 18, 2026, 1:17 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionModerate confidence

1Y Price: -84.68%FCF (TTM): 46.72%

What changed

The stock fell 84.68% over the last year. Free cash flow grew 46.72% over the trailing twelve months.

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.

What would invalidate this read

This read is wrong if revenue rolls over, margins compress again, or free cash flow keeps deteriorating. In that case the selloff would be catching up with weaker business quality rather than just a lower multiple.

Performance

Return analysis

Company profile

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system.

CEOJames Rolke

SectorHealthcare

IndustryBiotechnology

Employees8

IPO dateNov 17, 2020

https://www.revbiosciences.com

Market multiples

Forward P/E—

EV/EBITDA0.88

Enterprise value-$7.97M

Stock splits

Jan 28, 2026↓ Reverse

Every 4 shares became 1

-75%

Jul 7, 2025↓ Reverse

Every 3 shares became 1

-67%

Jan 28, 2025↓ Reverse

Every 16 shares became 1

-94%

Jan 25, 2024↓ Reverse

Every 30 shares became 1

-97%

Feb 1, 2023↓ Reverse

Every 35 shares became 1

-97%

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-154.77%▼23.4ppvs FY2025

Analyst consensus

RatingBuy

Target price—

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.88 · Revenue est —

View

NASDAQ · REVB

Revelation Biosciences, Inc.

Healthcare · Biotechnology

$0.95▲ 3.26% ($0.03)at close

After hours$0.97▲ 1.98%7:30 PM ET

52-week

$0.88$6.76

Market cap

$3.71M

P/E

-0.14

EPS (TTM)

-$2.81

Next earnings

Nov 5, 2026

No multiple

What the market price implies · Reverse DCF

Selected forecast · Base scenario

Unavailable · actual 10-year annualized revenue growth

Year 1 growth: —

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.95

Estimated value / share

Unavailable

Base scenario

USD

Need reported operating working-capital balances or comparable changes in working capital to forecast reinvestment; an unknown requirement cannot be treated as zero.

Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.

Year 1 growth — · Ending margin — · Discount rate 7%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: Not supplied
Data refreshed: Sep 18, 2026, 1:17 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionModerate confidence

1Y Price: -84.68%FCF (TTM): 46.72%

What changed

The stock fell 84.68% over the last year. Free cash flow grew 46.72% over the trailing twelve months.

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.

What would invalidate this read

Performance

Return analysis

Company profile

CEOJames Rolke

SectorHealthcare

IndustryBiotechnology

Employees8

IPO dateNov 17, 2020

https://www.revbiosciences.com

Market multiples

Forward P/E—

EV/EBITDA0.88

Enterprise value-$7.97M

Stock splits

Jan 28, 2026↓ Reverse

Every 4 shares became 1

-75%

Jul 7, 2025↓ Reverse

Every 3 shares became 1

-67%

Jan 28, 2025↓ Reverse

Every 16 shares became 1

-94%

Jan 25, 2024↓ Reverse

Every 30 shares became 1

-97%

Feb 1, 2023↓ Reverse

Every 35 shares became 1

-97%

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-154.77%▼23.4ppvs FY2025

Analyst consensus

RatingBuy

Target price—

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.88 · Revenue est —

View